Trends in GPCR drug discovery: new agents, targets and indications. (Q47597808)

PubMed publication ID

29075003

4 February 2018

http://europepmc.org/abstract/MED/29075003

title

Trends in GPCR drug discovery: new agents, targets and indications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

Alexander S Hauser

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

author name string

Misty M Attwood

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

Mathias Rask-Andersen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

Helgi B Schiöth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

publication date

27 October 2017

1 reference

PubMed publication ID

29075003

4 February 2018

http://europepmc.org/abstract/MED/29075003

published in

Nature Reviews Drug Discovery

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

page(s)

829-842

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

The GRAFS classification system of G-protein coupled receptors in comparative perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Teaching old receptors new tricks: biasing seven-transmembrane receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Biased ligands at G-protein-coupled receptors: promise and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

"Chemokine receptors as therapeutic targets: Why aren't there more drugs?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Metabotropic glutamate receptors as drug targets: what's new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G protein-coupled receptors as therapeutic targets for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G Protein-Coupled Receptors in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G protein-coupled receptors: novel targets for drug discovery in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Nanobodies and their Use in GPCR Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Tools for GPCR drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

New paradigms in GPCR drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Allostery and Biased Agonism at Class B G Protein-Coupled Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Emerging paradigms in GPCR allostery: implications for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Recent updates on GPCR biased agonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

GPCRdb: an information system for G protein-coupled receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

DrugBank 4.0: shedding new light on drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Alignment-free $d_2^*$ oligonucleotide frequency dissimilarity measure improves prediction of hosts from metagenomically-derived viral sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Open Targets: a platform for therapeutic target identification and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

How many drug targets are there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Trends in the exploitation of novel drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

A comprehensive map of molecular drug targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Opportunities for therapeutic antibodies directed at G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G protein-coupled receptors as targets for anti-diabetic therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Angiotensin II for the Treatment of Vasodilatory Shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Allosteric modulation and functional selectivity of G protein-coupled receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Development of allosteric modulators of GPCRs for treatment of CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Polypharmacology: challenges and opportunities in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Polypharmacology of dopamine receptor ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Proteomics. Tissue-based map of the human proteome

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRD.2017.178

21 January 2018

https://api.crossref.org/works/10.1038%2FNRD.2017.178

7 January 2021

inferred from DOI database lookup

Anatomical profiling of G protein-coupled receptor expression

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Novel Therapeutic GPCRs for Psychiatric Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

The role of G protein-coupled receptors in the pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

The therapeutic potential of G-protein coupled receptors in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Use of antidiabetic drugs in the U.S., 2003-2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Type 2 diabetes mellitus: a review of current trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

GPR119: "double-dipping" for better glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Dopaminergic drugs in type 2 diabetes and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G Protein-Coupled Receptor Signaling in Stem Cells and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Insights into bombesin receptors and ligands: Highlighting recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Bombesin-like peptides: studies on food intake and social behaviour with receptor knock-out mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Galanin receptors as a potential target for neurological disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Inhibitors of HIV-1 protease: a major success of structure-assisted drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

A Molecular Pharmacologist's Guide to G Protein-Coupled Receptor Crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

From G Protein-coupled Receptor Structure Resolution to Rational Drug Design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Structures of G protein-coupled receptors reveal new opportunities for drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Editorial overview: New technologies: GPCR drug design and function — exploiting the current (of) structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Structure-based discovery of opioid analgesics with reduced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Pharmacology: Inside-out receptor inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

G-protein-coupled receptors and signaling networks: emerging paradigms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

A Pluridimensional View of Biased Agonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

The dynamic process of β(2)-adrenergic receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Biased Agonism of the Angiotensin II Type I Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

In vivo veritas, the next frontier for functionally selective GPCR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Gut chemosensing mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Commensal bacteria make GPCR ligands that mimic human signalling molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Recognition of bacterial signal peptides by mammalian formyl peptide receptors: a new mechanism for sensing pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Extrasensory perception: odorant and taste receptors beyond the nose and mouth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

How Ligands Illuminate GPCR Molecular Pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Allosteric "beta-blocker" isolated from a DNA-encoded small molecule library

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Cornerstones of CRISPR-Cas in drug discovery and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Can you teach old drugs new tricks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

21 January 2018

2016 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2017.178

Enhanced morphine analgesia in mice lacking beta-arrestin 2

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRD.2017.178

31 March 2020

12 December 2020

GCRDb: a G-protein-coupled receptor database

1 reference

12 December 2020

Genome duplication events and functional reduction of ploidy levels in sturgeon (Acipenser, Huso and Scaphirhynchus)

1 reference

12 December 2020

Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression

1 reference

12 December 2020

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

1 reference

12 December 2020

The Latest Innovations in the Drug Pipeline for Multiple Sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2017.178

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

Dimensions Publication ID

13 May 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6882681&resulttype=core&format=json

13 May 2020

PubMed publication ID

29075003

1 reference